Navigation Links
Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Knee Osteoarthritis; Core Patent Issued
Date:1/5/2011

on November 9, 2010 the US Patent Office issued a key Carbylan patent covering novel modified hyaluronic acid polymer compositions and methods (US Pat. 7,829,118). This patent protects the composition of matter for Hydros and Hydros TA as well as the proprietary chemistry used to trap the steroidal suspension inside the hydrogel component for Hydros TA from generic competition until 2030.

About Hydros and Hydros TA Joint Therapies

Hydros Joint Therapy ("Hydros") is an intra-articular injection therapy comprised of non-animal sourced hyaluronic acid (HA) which is chemically modified to form hydrogel beads.   Hydros is biodegradable and resides in the joint for up to thirty days and is expected to provide sustained pain relief for up to six months with a single injection. Traditional viscosupplements are cleared from the joint in less than a week.  Hydros TA Joint Therapy ("Hydros TA") is a novel dual mode viscosupplement which traps 10mg of triamcinolone acetonide (corticosteroid) inside the Hydros hydrogel beads. Hydros TA is expected to provide faster acting, longer lasting pain relief than either viscosupplements or steroids alone.  Hydros TA allows for sustained local delivery of a low dose steroid reducing the risk of systemic steroid exposure and the potential cartilage degradation associated with steroid injections in the knee.  There is currently no similar viscosupplement/steroid combination product available to treat the pain associated with osteoarthritis.  

About Osteoarthritis

Osteoarthritis (OA), also known as degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities involving degradation of joints.   Knee osteoarthritis is the most common type of osteoarthritis. More than 10 million Americans have knee osteoarthritis. It is also the most common cause of disability in the United States.

About Carbylan BioSurgery

Carbylan was founded in 2005 to deve
'/>"/>

SOURCE Carbylan BioSurgery, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Completes Acquisition of Sadra Medical
2. SRI International Completes Integration of Sarnoff Corporation
3. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
4. Boston Scientific Completes Sale of Neurovascular Business
5. Henry Schein Completes Acquisition of Provet Holdings Limited
6. Hanger Orthopedic Group, Inc. Completes Exchange Offer of 7 1/8% Senior Notes Due 2018
7. WebMD Completes Redemption of 3 1/8% Convertible Notes
8. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
9. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
10. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
11. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... China separating membrane market has witnessed robust development ... years, albeit as a later starter. In 2012, the size ... approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. ... membrane market will continue its growth rate by around 20% ... will jump to roughly RMB25 billion. An integrated ...
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG; "IGI" or ... of $125 million aggregate principal amount of 3.75% Convertible ... offered and sold only to qualified institutional buyers pursuant ... as amended (the "Securities Act"). The Notes ... year, payable semiannually in arrears on June 15 and ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4
... plc , (LSE: SHP, Nasdaq: SHPGY ), the ... and Drug Administration (FDA) approved the use of once-daily ... for the treatment of attention deficit hyperactivity disorder (ADHD) in ... a total treatment program. The approval is based on results ...
... YORK, Feb. 28, 2011 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... the Company,s Chief Executive Officer, will be presenting at ... Conference (New York, NY)Wednesday, March 2, 201111:00am ETCowen & ... MA)Monday, March 7, 2011 4:45pm ETROTH 23rd Annual OC ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations 2
(Date:12/21/2014)... 21, 2014 AngelWeddingDress.com’s new collection of ... a total of 1,000 new designs in this collection, ... spring 2015. , AngelWeddingDress.com promises to provide ... with wardrobe essentials while many fashion trends come and ... customer service team at AngelWeddingDress.com is ready to assist. ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Recently, one ... world, LunaDress Prom Shop has introduced its ... Christmas Sale, offering big discounts on all its prom ... off. , LunaDress insists on providing top quality dress ... and it is considered as one of the best ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... 2014 SCI explores disability ... and systemic barriers for disabled athletes with Aaron ... has a condition called juvenile macular degeneration, where he ... he adapted his athletic ambitions to his vision and ... triathlon to pioneer the way for other blind and ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 CannabisClassifieds.com celebrates marijuana’s ... The only one of its kind, the site has ... local marijuana for 14 years running. It uniquely combines ... to make cannabis readily available to the masses. Assuring ... grasping the golden ring of public approval. , ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:New Prom Dresses From One Of The Best Prom Dresses Online Shops, LunaDress Prom Shop 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2
... diet, researchers say , WEDNESDAY, July 8 (HealthDay News) -- ... common amino acids in vegetable protein seems to lower blood ... shows that a 4.72 percent higher intake of glutamic acid ... 1.5- to 3-point reduction in average systolic blood pressure (the ...
... 8 Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... non-invasive, topically administered products, today announced they have ... pivotal Phase 3 clinical study for Ketotransdel(R), a ... acute pain. , , Based on ...
... N.Y., July 8 The Max Cure Foundation -- a ... -- announced today its first charity benefit, the first annual ... take place on Saturday, August 22, from 2:00 - 6:00 ... the East Hampton Indoor Tennis Club, 175 Daniels Hole Road, ...
... July 8 Perot Systems Corporation (NYSE: ... an agreement with the Hunan Provincial Government of the ... to provide IT consulting services for healthcare organizations and ... the Provincial Government and in alignment with the Chinese ...
... ... High Definition videoconferencing, audiovisual (AV), networked solutions and services to offer video conferencing ... global room affiliates. , ... Denver, CO and Camarillo, CA (PRWEB) July 8 -- Affinity ...
... ... popularity. These parts washers are cost effective and quick solutions for companies that need ... ... Midbrook, a Jackson, MI based manufacturer of industrial parts washing systems, medical decontamination systems, ...
Cached Medicine News:Health News:Vegetable Amino Acid Lowers Blood Pressure 2Health News:Vegetable Amino Acid Lowers Blood Pressure 3Health News:Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 2Health News:Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 2Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 3Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 4Health News:The Max Cure Foundation Announces Its First Charity Benefit: The 'Roar for a Cure' Carnival to Be Held on Saturday, August 22, 2009 5Health News:Perot Systems Selected to Implement Health Information Systems in China 2Health News:Perot Systems Selected to Implement Health Information Systems in China 3Health News:Affinity VideoNet Partners With Providea Conferencing 2Health News:Affinity VideoNet Partners With Providea Conferencing 3Health News:Refurbished and Used Industrial Parts Washers Grow in Popularity 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... continues the "Consensus Concept" approach to design ... experience of a Scientific Advisory Board. The ... incorporates state-of-the-art features. Consensus Knee implants are ... stability and allow near normal kinematics. The ...
Medicine Products: